China · Delayed Price · Currency is CNY Sansure Biotech Statistics
Total Valuation
Sansure Biotech has a market cap or net worth of CNY 11.58 billion. The enterprise value is 8.77 billion.
| Market Cap | 11.58B |
| Enterprise Value | 8.77B |
Important Dates
The next estimated earnings date is Thursday, April 30, 2026.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | Sep 23, 2025 |
Share Statistics
Sansure Biotech has 574.18 million shares outstanding. The number of shares has increased by 14.18% in one year.
| Current Share Class | 574.18M |
| Shares Outstanding | 574.18M |
| Shares Change (YoY) | +14.18% |
| Shares Change (QoQ) | +63.60% |
| Owned by Insiders (%) | 42.07% |
| Owned by Institutions (%) | 8.07% |
| Float | 280.59M |
Valuation Ratios
The trailing PE ratio is 50.05 and the forward PE ratio is 34.58.
| PE Ratio | 50.05 |
| Forward PE | 34.58 |
| PS Ratio | 6.94 |
| PB Ratio | 1.60 |
| P/TBV Ratio | 1.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 57.92 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 29.72, with an EV/FCF ratio of -40.80.
| EV / Earnings | 32.30 |
| EV / Sales | 5.25 |
| EV / EBITDA | 29.72 |
| EV / EBIT | 75.89 |
| EV / FCF | -40.80 |
Financial Position
The company has a current ratio of 4.88, with a Debt / Equity ratio of 0.15.
| Current Ratio | 4.88 |
| Quick Ratio | 4.39 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | 3.74 |
| Debt / FCF | -5.13 |
| Interest Coverage | 6.03 |
Financial Efficiency
Return on equity (ROE) is 3.09% and return on invested capital (ROIC) is 2.53%.
| Return on Equity (ROE) | 3.09% |
| Return on Assets (ROA) | 0.80% |
| Return on Invested Capital (ROIC) | 2.53% |
| Return on Capital Employed (ROCE) | 1.38% |
| Weighted Average Cost of Capital (WACC) | 7.93% |
| Revenue Per Employee | 711,688 |
| Profits Per Employee | 115,725 |
| Employee Count | 2,346 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 0.91 |
Taxes
In the past 12 months, Sansure Biotech has paid 15.01 million in taxes.
| Income Tax | 15.01M |
| Effective Tax Rate | 6.25% |
Stock Price Statistics
The stock price has increased by +0.60% in the last 52 weeks. The beta is 0.78, so Sansure Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.78 |
| 52-Week Price Change | +0.60% |
| 50-Day Moving Average | 19.80 |
| 200-Day Moving Average | 20.52 |
| Relative Strength Index (RSI) | 57.37 |
| Average Volume (20 Days) | 5,671,304 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sansure Biotech had revenue of CNY 1.67 billion and earned 271.49 million in profits. Earnings per share was 0.40.
| Revenue | 1.67B |
| Gross Profit | 1.29B |
| Operating Income | 115.53M |
| Pretax Income | 240.18M |
| Net Income | 271.49M |
| EBITDA | 285.98M |
| EBIT | 115.53M |
| Earnings Per Share (EPS) | 0.40 |
Balance Sheet
The company has 4.01 billion in cash and 1.10 billion in debt, with a net cash position of 2.90 billion or 5.05 per share.
| Cash & Cash Equivalents | 4.01B |
| Total Debt | 1.10B |
| Net Cash | 2.90B |
| Net Cash Per Share | 5.05 |
| Equity (Book Value) | 7.22B |
| Book Value Per Share | 12.42 |
| Working Capital | 4.22B |
Cash Flow
In the last 12 months, operating cash flow was 199.95 million and capital expenditures -414.85 million, giving a free cash flow of -214.90 million.
| Operating Cash Flow | 199.95M |
| Capital Expenditures | -414.85M |
| Free Cash Flow | -214.90M |
| FCF Per Share | -0.37 |
Margins
Gross margin is 77.02%, with operating and profit margins of 6.92% and 16.26%.
| Gross Margin | 77.02% |
| Operating Margin | 6.92% |
| Pretax Margin | 14.39% |
| Profit Margin | 16.26% |
| EBITDA Margin | 17.13% |
| EBIT Margin | 6.92% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.54, which amounts to a dividend yield of 2.66%.
| Dividend Per Share | 0.54 |
| Dividend Yield | 2.66% |
| Dividend Growth (YoY) | 19.33% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 122.80% |
| Buyback Yield | -14.18% |
| Shareholder Yield | -11.47% |
| Earnings Yield | 2.34% |
| FCF Yield | -1.86% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 1, 2022. It was a forward split with a ratio of 1.48.
| Last Split Date | Jun 1, 2022 |
| Split Type | Forward |
| Split Ratio | 1.48 |
Scores
Sansure Biotech has an Altman Z-Score of 4.79 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.79 |
| Piotroski F-Score | 4 |